Literature DB >> 7901229

Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.

W C Dougall1, X Qian, M I Greene.   

Abstract

Growth factor receptors such as the epidermal growth factor receptor (EGFR) and the p185c-neu protein serve vital roles in the transduction of differentiation, developmental, or mitogenic signaling within normal cells. Two methods of analysis suggest that the inappropriately high expression of either protein tyrosine kinase promotes malignant transformation. First, data from in vitro experiments indicate that overexpression of either EGFR or p185c-neu (or the human homolog c-erbB-2) transforms cell-lines. Second, analysis of primary tumors and tumor cell-lines derived from many epithelial tissues (breast, stomach, ovary, and pancreas) show growth factor receptor gene amplification and elevated protein levels. The physical and functional interaction of p185c-neu and EGFR leads to the formation of a highly active, heterodimeric tyrosine kinase complex which synergistically activates cellular transformation. Anti-receptor antibodies have shown potential utility for the down modulation of these cell-surface proteins and suppression of the malignant phenotype. Design of organic antibody "mimetics" based on the structure of antireceptor antibodies may provide useful therapies and biological reagents to affect growth factor receptor function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901229     DOI: 10.1002/jcb.240530108

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  p185, an immunodominant epitope, is an autoantigen mimotope.

Authors:  Sanjeev Kumar; John A Hinks; Joseph Maman; Chelliah T Ravirajan; Laurence H Pearl; David A Isenberg
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  γ-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling.

Authors:  R A Ahmed; O A Alawin; P W Sylvester
Journal:  Cell Prolif       Date:  2016-06-21       Impact factor: 6.831

5.  Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.

Authors:  M Bolla; B Rostaing-Puissant; S P Bottari; M Chedin; J Marron-Charriere; M Colonna; E Berland; E Chambaz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 6.  Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors.

Authors:  D M O'Rourke; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

7.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.

Authors:  Chi-Hong B Chen; George A Chernis; Van Q Hoang; Ralf Landgraf
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

8.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.

Authors:  X Qian; C M LeVea; J K Freeman; W C Dougall; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Activation of c-fos gene expression by a kinase-deficient epidermal growth factor receptor.

Authors:  E R Eldredge; G M Korf; T A Christensen; D C Connolly; M J Getz; N J Maihle
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.